Revance Therapeutics CEO L Browne's 2018 pay jumps 37% to $4.7M
Revance Therapeutics reports 2018 executive compensation
By ExecPay News
Published: March 25, 2019
Revance Therapeutics reported fiscal year 2018 executive compensation information on March 25, 2019.
In 2018, seven executives at Revance Therapeutics received on average a compensation package of $2.2M, a 14% decrease compared to previous year.
Average pay of disclosed executives at Revance Therapeutics
L. Daniel Browne, Chief Executive Officer, received $4.7M in total, which increased by 37% compared to 2017. 61% of Browne's compensation, or $2.9M, was in option awards. Browne also received $410K in non-equity incentive plan, $565K in salary, $823K in stock awards, as well as $9.2K in other compensation.
Caryn G. McDowell, General Counsel, received a compensation package of $2.7M. 68% of the compensation package, or $1.8M, was in option awards.
Abhay Joshi, Chief Operating Officer, earned $2.2M in 2018, a 11% increase compared to previous year.
Tobin C. Schilke, Chief Financial Officer, received $2M in 2018.
Todd E. Zavodnick, Former Chief Commercial Officer and President, Aesthetics & Therapeutics, earned $1.5M in 2018, a 52% decrease compared to previous year.
Lauren P. Silvernail, Chief Financial Officer, received $1.3M in 2018, which decreases by 17% compared to 2017.
Cyril Allouche, Former Head of Finance and Corporate Controller, Principal Accounting Officer, earned $799K in 2018.
Related executives
L Browne
Revance Therapeutics
Chief Executive Officer
Tobin Schilke
Revance Therapeutics
Chief Financial Officer
Abhay Joshi
Revance Therapeutics
Chief Operating Officer
Caryn McDowell
Revance Therapeutics
General Counsel
Cyril Allouche
Revance Therapeutics
Former Head of Finance and Corporate Controller, Principal Accounting Officer
Todd Zavodnick
Revance Therapeutics
Former Chief Commercial Officer and President, Aesthetics & Therapeutics
Lauren Silvernail
Revance Therapeutics
Chief Financial Officer
You may also like
Source: SEC filing on March 25, 2019.